Current status and future of target-based therapeutics

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• The 21st century has ushered in a new era of cancer therapy with molecular targeted drugs.
• Traditional chemotherapy relies on cytotoxic screening, while targeted drug development involves identifying and inhibiting specific molecular targets.
• Examples like Glivec show promise, but others have failed, highlighting the need for improved methodologies.

Purpose of the Study:

• To review the current and future status of molecular targeted drugs in cancer therapy.
• To emphasize the importance of efficient methods for identifying effective molecular targeted drugs.
• To discuss key considerations for successful clinical application and drug development.

Main Methods:

• Review of existing literature on molecular targeted drugs and cancer therapy.
• Analysis of methodologies for drug target identification and molecule screening.
• Discussion of translational studies and their role in drug development.

Main Results:

• Molecular targeted drug development offers a more logical approach compared to traditional chemotherapy.
• The success of targeted therapies depends on accurate target identification and drug efficacy.
• Translational research is essential for evaluating and refining molecular targeted drugs.

Conclusions:

• Efficient methods are needed to discover effective molecular targeted drugs.
• Key factors for success include identifying the correct molecular targets and optimizing clinical administration.
• Continuous evaluation through translational studies is vital for advancing cancer therapy with molecular targeted drugs.